Shruti Bhat PhD, MBA, Operations Excellence Expert
  • Home
  • About Shruti
  • Books
  • Insights
  • Operational Excellence
  • Research
    • Innovation Management
    • Leading Research and Development
    • Developer's Diary
  • Case Studies
  • Tools
    • Whitepapers
    • Articles >
      • Business Transformation
      • Process Improvement
      • Business Continuity
      • Change Management
      • Digital Transformation
      • Quality Improvement
    • Checklists and Templates
    • Free eBook
    • Videos
  • Blog
  • Engage Shruti
    • Consulting >
      • Operational Excellence Consulting
      • Business Transformation Consulting
      • Innovation Management Consulting
    • Workshops
  • Contact

Pharma business updates

1/5/2010

0 Comments

 
Novartis makes offer to buy Alcon for $39 billion.
Novartis AG offered to buy the rest of Alcon Inc., the world's largest eye-care company, from Nestle SA and shareholders for a total of $39.3 billion, as Chief Executive Officer Daniel Vasella expands into products for eye surgery.  The deal increases Novartis' ownership of Alcon to 77 percent, possibly bringing the company closer to its goal of becoming a global healthcare conglomerate. Novartis also bid to buy out minority shareholders and offered 2.80 Novartis share for each Alcon share.  

Nabi signs licensing deal with Glaxo for nicotine vaccine.
Nabi Biopharmaceuticals "has signed a licensing deal" with GlaxoSmithKline "that could produce a huge payday if the anti-smoking drug can be successfully brought to market." Nabi said a unit of Glaxo "has agreed to pay $40 million initially for the exclusive worldwide licensing rights to the drug, called NicVax [nicotine conjugate vaccine]." 
According to a published report, Nabi could receive over $500 million in option fees and regulatory, development and sales milestones and  is running one late-stage clinical study of NicVax and plans to start another one. 

Bristol-Myers splits from nutrition company to focus on biotech drugs.
Bristol-Myers Squibb Co. will split off its 83 percent stake in Mead Johnson Nutrition Co., the maker of Enfamil infant formula, to focus on biotechnology medicines." Bristol-Meyers said about "a third" of its "drugs in development are biotechnology compounds. Bristol CEO "James M. Cornelius has been selling assets to raise money for acquisitions and cutting jobs to lower costs by $2.5 billion by 2012, when the blood-thinner Plavix [clopidogrel bisulfate] faces generic competition."  

Abbott buys potential chronic pain drug for up to $190 million.
Abbott Laboratories is reportedly buying a potential chronic pain drug from PanGenetics BV for as much as $190 million." Abbott "said the drug is in early-stage clinical testing as a treatment for pain cause by arthritis," and could be tested "against chronic lower back pain, cancer pain, and diabetic nerve pain." PanGenetics "will receive $170 million upfront from Abbott, and $20 million in milestone payments if the drug advances through development. Although the drug, called PG110, is "still in early human clinical trials, Abbott executives say they expect to one day launch the drug in both injected form and an intravenous formulation."

Disclaimer : In addition to Terms and Condition for this blog, this information is for knowledge purpose only and should not be interpreted as business advise. 
Follow Shruti on Twitter, Facebook, YouTube, LinkedIn
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Shruti Bhat, global leader in business turnaround, operational excellence and continuous improvement
    To contact Dr. Shruti Bhat text or WhatsApp at 1.403.969.6219

    New Book Released!

    Revolutionizing Industries with Lean Six Sigma

    Shruti's YouTube Channel ...

    Picture

    Blog Categories

    All
    3D Printing
    Agile
    Artificial Intelligence
    Automation
    Biotechnology
    Books
    Business Continuity
    Business Turnaround
    Case Studies
    Change Management
    Checklists
    Chemical Industry
    Continuous Improvement
    Design Thinking
    Digitalization
    Drug Delivery
    External News Links
    Hall Of Fame
    Healthcare
    Hoshin Kanri
    HR Development
    Innovation
    Insights
    ISO
    Just In Time
    Kaizen
    Leadership
    LEAN
    Lean Six Sigma
    Life Sciences
    Machine Learning
    Manufacturing
    Medical Devices
    Mistake Proofing
    Motivational Cards
    MSMEs
    Nanotechnology
    Operational Excellence
    Packaging
    Patents
    Personal Products
    Process Improvement
    Product Development
    Productivity Increase
    QbD
    Quality Management
    R&D Leadership
    Robotics
    Service Industry
    Six Sigma
    Strategy
    Supply Chain Logistics
    Telecom Industry
    Templates
    TQM
    Videos
    Voice Of Customer
    Whitepaper
    Workshops

    Shruti's books...

    Picture
    top ten strategic decision-making tools for operational excellence
    shruti bhat, business process management, continuous improvement
    kaizen for pharmaceutcials, medical devices and biotech industry book by Dr Shruti Bhat
    Book on Continuous improvement tools by Dr Shruti Bhat
    kaizen for leaders, continuous process improvement tool to increase profit and organizational excellence by shruti bhat
    kaizen, shruti bhat, continuous improvement, quality, operations management
    how to lead a successful business transformation
    leading organizations through crisis
    emotional intelligence
    how to overcome challenges of creating effective teams
    modular kaizen Vs Blitz kaizen
    How to increase employee engagement as a new boss

Connect with Dr. Shruti Bhat at- ​Twitter, YouTube, LinkedIn​

© Copyright 1992- 2025 Dr. Shruti Bhat ALL RIGHTS RESERVED.
See Terms and Conditions for details on this site usage.
Subscribe to Operational Excellence Academy YouTube Channel
​Subscribe to Operational Excellence Academy YouTube Channel
SHRUTI BHAT, CONTACT
Click to connect.
Created by Macro2Micro Media